Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia [Hematologic Malignancy]
Conclusion Patients with cHL who are event free at 2 years have an excellent outcome regardless of baseline prognostic factors. All patients with cHL had an enduring increased risk of death compared with the general population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Hapgood, Zheng, Sehn, Villa, Klasa, Gerrie, Shenkier, Scott, Gascoyne, Slack, Parsons, Morris, Pickles, Connors, Savage Tags: Combined Modality Hematologic Malignancy Source Type: research

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma [Hematologic Malignancy]
Conclusion Enzastaurin did not significantly improve DFS in patients with high-risk DLBCL after achieving complete response to R-CHOP. Achievement of a complete response may have abrogated the prognostic significance of cell of origin by immunohistochemistry. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Crump, Leppa, Fayad, Lee, Di Rocco, Ogura, Hagberg, Schnell, Rifkin, Mackensen, Offner, Pinter-Brown, Smith, Tobinai, Yeh, Hsi, Nguyen, Shi, Hahka-Kemppinen, Thornton, Lin, Kahl, Schmitz, Savage, Habermann Tags: Chemotherapy, Translational Oncology Hematologic Malignancy Source Type: research

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors [Urologic Oncology]
Conclusion TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs with an acceptable safety profile. Given higher rates of favorable response, progression-free survival, and overall survival compared with prior first-line studies, TIP warrants further study in this population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Feldman, Hu, Dorff, Lim, Patil, Woo, Carousso, Hughes, Sheinfeld, Bains, Daneshmand, Ketchens, Bajorin, Bosl, Quinn, Motzer Tags: Clinical Trials, Chemotherapy Urologic Oncology Source Type: research

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis [Neurooncology]
Conclusion The most impactful biomarker for posterior fossa ependymoma is molecular subgroup affiliation, independent of other demographic or treatment variables. However, both EPN_PFA and EPN_PFB still benefit from increased extent of resection, with the survival rates being particularly poor for subtotally resected EPN_PFA, even with adjuvant radiation therapy. Patients with EPN_PFB who undergo gross total resection are at lower risk for relapse and should be considered for inclusion in a randomized clinical trial of observation alone with radiation reserved for those who experience recurrence. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Ramaswamy, Hielscher, Mack, Lassaletta, Lin, Pajtler, Jones, Luu, Cavalli, Aldape, Remke, Mynarek, Rutkowski, Gururangan, McLendon, Lipp, Dunham, Hukin, Eisenstat, Fulton, van Landeghem, Santi, van Veelen, Van Meir, Osuka, Fan, Muraszko, Tirapelli, Oba-Sh Tags: Brain Tumors, Surgery, Radiation, Translational Oncology, CNS Tumors, Gene Expression and Profiling Neurooncology Source Type: research

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study [Breast Cancer]
Conclusion This phase Ib study describes preliminary evidence of clinical activity and a potentially acceptable safety profile of pembrolizumab given every 2 weeks to patients with heavily pretreated, advanced TNBC. A single-agent phase II study examining a 200-mg dose given once every 3 weeks (ClinicalTrials.gov identifier: NCT02447003) is ongoing. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Nanda, Chow, Dees, Berger, Gupta, Geva, Pusztai, Pathiraja, Aktan, Cheng, Karantza, Buisseret Tags: Chemotherapy, Phase I and Clinical Pharmacology, Breast Imaging Breast Cancer Source Type: research

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence [Breast Cancer]
Purpose To investigate adherence to endocrine treatment and its relationship with disease-free survival (DFS) in the Breast International Group (BIG) 1-98 clinical trial. Methods The BIG 1-98 trial is a double-blind trial that randomly assigned 6,193 postmenopausal women with hormone receptor–positive early breast cancer in the four-arm option to 5 years of tamoxifen (Tam), letrozole (Let), or the agents in sequence (Let-Tam, Tam-Let). This analysis included 6,144 women who received at least one dose of study treatment. Conditional landmark analyses and marginal structural Cox proportional hazards models were used t...
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Chirgwin, Giobbie-Hurder, Coates, Price, Ejlertsen, Debled, Gelber, Goldhirsch, Smith, Rabaglio, Forbes, Neven, Lang, Colleoni, Thurlimann Tags: Hormonal Therapy Breast Cancer Source Type: research

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma [Rapid Communication]
Conclusion We conclude that KIR3LD1 and HLA-B allele combinations can have a prognostic impact on patient survival after treatment with anti-GD2 mAb that relies on NK-ADCC. The survival advantage seen in noninteracting combinations supports the therapeutic disinhibition of individuals with strongly interacting KIR and ligand pairs. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Forlenza, Boudreau, Zheng, Le Luduec, Chamberlain, Heller, Cheung, Hsu Tags: Neuroblastoma, Rapid Communications, Rapid Communications, Immunology/Immunobiology Source Type: research

Sticking to It: Improving Outcomes by Increasing Adherence [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Hershman Tags: Hormonal Therapy EDITORIALS Source Type: research

The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Barrett, Bagatell Tags: Neuroblastoma EDITORIALS Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Reply to T. Magnes et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Deenen, Cats, Severens, Beijnen, Schellens Tags: CORRESPONDENCE Source Type: research

Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Magnes, Melchardt, Weiss, Hufnagl, Greil, Egle Tags: CORRESPONDENCE Source Type: research

Reply to T.A. Yap et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Sweis, Ratain Tags: CORRESPONDENCE Source Type: research

Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Yap, Banerji, de Bono, Workman Tags: CORRESPONDENCE Source Type: research

Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Beumer, Tawbi, Ivy Tags: CORRESPONDENCE Source Type: research

Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Porta, Cosmai, Gallieni, Perazella Tags: CORRESPONDENCE Source Type: research

Obvious Pitfall in the Estimation of Renal Dysfunction [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Shimokata, Yasuda, Ando Tags: CORRESPONDENCE Source Type: research

Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Launay-Vacher Tags: CORRESPONDENCE Source Type: research

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)–positive breast cancers was identified for adaptation. Methods The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The CCO guideline was reviewed for developmental rigor and content applicability. Results On the basis of the content review of the CCO guideline, the ASCO Panel agreed that, in gene...
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Denduluri, Somerfield, Eisen, Holloway, Hurria, King, Lyman, Partridge, Telli, Trudeau, Wolff Tags: Epidemiology, Chemotherapy, Combined Modality, Hormonal Therapy, ASCO Guidelines, Non-ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid [BIOLOGY OF NEOPLASIA]
Conclusion The study shows that CSF harbors clinically relevant genomic alterations in patients with CNS cancers and should be considered for liquid biopsies to monitor tumor evolution in the CNS. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Pentsova, Shah, Tang, Boire, You, Briggs, Omuro, Lin, Fleisher, Grommes, Panageas, Meng, Selcuklu, Ogilvie, Distefano, Shagabayeva, Rosenblum, DeAngelis, Viale, Mellinghoff, Berger Tags: BIOLOGY OF NEOPLASIA Source Type: research

Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer [Palliative and Supportive Care]
Conclusion Patients with advanced cancer who report recent discussions of prognosis/life expectancy with their oncologists come to have a better understanding of the terminal nature of their illnesses. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Epstein, Prigerson, OReilly, Maciejewski Tags: Prognostic Studies, Supportive Care, Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Diagnosis & Staging, End of Life, Outcomes Research, Palliative Care, Epidemiology, Diagnosis & Source Type: research

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma [Melanoma]
Conclusion Adoptive cell transfer can mediate durable complete regressions in 24% of patients with metastatic melanoma, with median survival> 3 years. Results were similar using chemotherapy preparative regimens with or without addition of TBI. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Goff, Dudley, Citrin, Somerville, Wunderlich, Danforth, Zlott, Yang, Sherry, Kammula, Klebanoff, Hughes, Restifo, Langhan, Shelton, Lu, Kwong, Ilyas, Klemen, Payabyab, Morton, Toomey, Steinberg, White, Rosenberg Tags: Translational Oncology, Melanoma, Immunology/Immunobiology Source Type: research

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrens Oncology Group Study AALL0232 [Pediatric Oncology]
Conclusion High-dose methotrexate is superior to Capizzi methotrexate for the treatment of high-risk B-acute lymphoblastic leukemia, with no increase in acute toxicity. Dexamethasone given during induction benefited younger children but provided no benefit and was associated with a higher risk of osteonecrosis among participants 10 years and older. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Larsen, Devidas, Chen, Salzer, Raetz, Loh, Mattano, Cole, Eicher, Haugan, Sorenson, Heerema, Carroll, Gastier-Foster, Borowitz, Wood, Willman, Winick, Hunger, Carroll Tags: Acute Lymphoblastic Leukemia Pediatric Oncology Source Type: research

Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group [Pediatric Oncology]
Conclusion Some 75% of highly selected pediatric patients with LPHL may be spared chemotherapy after surgical resection alone. Pediatric LPHL has excellent EFS with chemotherapy that is less intensive than standard regimens;> 90% of patients can avoid radiation therapy. The salvage rate for the few relapses is high, with 100% survival overall. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Appel, Chen, Buxton, Hutchison, Hodgson, Ehrlich, Constine, Schwartz Tags: Combined Modality, Hodgkin's Disease Pediatric Oncology Source Type: research

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer [Clinical Trials]
This study aims to externally validate this model in an independent cohort (N = 250). Patients and Methods Patients age ≥ 65 years with a solid tumor, fluent in English, and who were scheduled to receive a new chemotherapy regimen were recruited from eight institutions. Risk of chemotherapy toxicity was calculated (low, medium, or high risk) on the basis of the prediction model before the start of chemotherapy. Chemotherapy-related toxicity was captured (grade 3 [hospitalization indicated], grade 4 [life threatening], and grade 5 [treatment-related death]). Validation of the prediction model was performed by calculatin...
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Hurria, Mohile, Gajra, Klepin, Muss, Chapman, Feng, Smith, Sun, De Glas, Cohen, Katheria, Doan, Zavala, Levi, Akiba, Tew Tags: Geriatric Oncology Clinical Trials Source Type: research

Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013 [Breast Cancer]
The objective of this study was to determine whether the 21-gene Recurrence Score (RS) provides clinically meaningful information in patients with de novo stage IV breast cancer enrolled in the Translational Breast Cancer Research Consortium (TBCRC) 013. Patients and Methods TBCRC 013 was a multicenter prospective registry that evaluated the role of surgery of the primary tumor in patients with de novo stage IV breast cancer. From July 2009 to April 2012, 127 patients from 14 sites were enrolled; 109 (86%) patients had pretreatment primary tumor samples suitable for 21-gene RS analysis. Clinical variables, time to first p...
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: King, Lyman, Gonen, Voci, De Brot, Boafo, Sing, Hwang, Alvarado, Liu, Boughey, McGuire, Van Poznak, Jacobs, Meszoely, Krontiras, Babiera, Norton, Morrow, Hudis Tags: Diagnosis & Staging, Surgery Breast Cancer Source Type: research

Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14 [Breast Cancer]
Purpose We determined the utility of the 21-Gene Recurrence Score (RS) in predicting late (> 5 years) distant recurrence (LDR) in stage I and II breast cancer within high and low-ESR1–expressing groups. Patients and Methods RS was assessed in chemotherapy/tamoxifen-treated, estrogen receptor (ER) –positive, node-positive National Surgical Adjuvant Breast and Bowel Project B-28 patients and tamoxifen-treated, ER-positive, node-negative B-14 patients. The association of the RS with risk of distant recurrence (DR) 0 to 5 years and those at risk> 5 years was assessed. An ESR1 expression cut point was optimiz...
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Wolmark, Mamounas, Baehner, Butler, Tang, Jamshidian, Sing, Shak, Paik Tags: Translational Oncology Breast Cancer Source Type: research

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment [Breast Cancer]
Conclusion In this prospective trial, patients with enhanced clinical risk and omitted chemotherapy on the basis of RS ≤ 11 had excellent 3-year survival. The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor–positive BC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Gluz, Nitz, Christgen, Kates, Shak, Clemens, Kraemer, Aktas, Kuemmel, Reimer, Kusche, Heyl, Lorenz-Salehi, Just, Hofmann, Degenhardt, Liedtke, Svedman, Wuerstlein, Kreipe, Harbeck Tags: Chemotherapy, Hormonal Therapy, Clinical Trials, Prognostic Studies Breast Cancer Source Type: research

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial [Hematologic Malignancy]
Conclusion These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Cortes, Saglio, Kantarjian, Baccarani, Mayer, Boque, Shah, Chuah, Casanova, Bradley-Garelik, Manos, Hochhaus Tags: Clinical Trials, Biological Therapy, Hematologic Hematologic Malignancy Source Type: research

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer [Rapid Communication]
Purpose Conventional radiotherapy (C-RT) treatment schedules for patients with prostate cancer typically require 40 to 45 treatments that take place from> 8 to 9 weeks. Preclinical and clinical research suggest that hypofractionation—fewer treatments but at a higher dose per treatment—may produce similar outcomes. This trial was designed to assess whether the efficacy of a hypofractionated radiotherapy (H-RT) treatment schedule is no worse than a C-RT schedule in men with low-risk prostate cancer. Patients and Methods A total of 1,115 men with low-risk prostate cancer were randomly assigned 1:1 to C-RT (73....
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Lee, Dignam, Amin, Bruner, Low, Swanson, Shah, DSouza, Michalski, Dayes, Seaward, Hall, Nguyen, Pisansky, Faria, Chen, Koontz, Paulus, Sandler Tags: Radiation, Rapid Communications Source Type: research

Making Radiation Therapy for Prostate Cancer More Economical and More Convenient [EDITORIAL]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Zietman Tags: Radiation EDITORIAL Source Type: research

Journal Honors Lillian Smyth, MD, MB BCh BAO, MRCPI (Ireland), As Recipient of the 2016 Journal of Clinical Oncology Young Investigator Award [JCO YIA]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Tags: JCO YIA Source Type: research

Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research

Reply to P. Blanchard et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Murphy, Galloway, Handorf, Egleston, Ridge Tags: CORRESPONDENCE Source Type: research

Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Blanchard, Garden Tags: CORRESPONDENCE Source Type: research

Reply to M.S. Copur et al and to M.C. Chamberlain [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Contessa, Johung, Goldberg, Chiang Tags: CORRESPONDENCE Source Type: research

Targetable Lung Cancer Brain Metastases: Improved Outcome [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Chamberlain Tags: CORRESPONDENCE Source Type: research

Is It Time to Reconsider Prophylactic Cranial Radiation in Non-Small-Cell Lung Cancer? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Copur, Ramaekers, Clark, Norvell, Gauchan Tags: CORRESPONDENCE Source Type: research

A Ruby Anniversary [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Finlay Tags: Emotions of the oncologist, Survivorship issues, All Art of Oncology Articles Source Type: research

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations [ASCO SPECIAL ARTICLE]
Purpose An American Society of Clinical Oncology (ASCO) panel considered the Cancer Care Ontario (CCO) recommendations on the role of patient and disease factors in selecting adjuvant therapy for women with early-stage breast cancer for endorsement. Methods ASCO staff reviewed the CCO guideline for methodologic rigor, and an ASCO panel of content experts reviewed the content of the recommendations. CCO Recommendations For making decisions regarding adjuvant therapy, nodal status, tumor size, estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2) status, tumor grade, and lymph...
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Henry, Somerfield, Abramson, Allison, Anders, Chingos, Hurria, Openshaw, Krop Tags: Epidemiology, Diagnosis & Staging, Chemotherapy, Hormonal Therapy, ASCO Guidelines, Non-ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study [Sarcomas]
Purpose Doxorubicin and trabectedin are considered active drugs in soft tissue sarcoma (STS). The combination of both drugs was hypothesized to be advantageous and safe on the basis of preclinical evidence and a previous phase I trial, respectively. The aim of this study was to compare the clinical outcome of trabectedin plus doxorubicin with doxorubicin as first-line treatment of advanced STS patients. Patients and Methods In this open-label randomized phase II trial, the main end point was progression-free survival (PFS). Trabectedin 1.1 mg/m2 in a 3-hour infusion plus doxorubicin 60 mg/m2 as the experimental arm and do...
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Martin-Broto, Pousa, de las Penas, Garcia del Muro, Gutierrez, Martinez-Trufero, Cruz, Alvarez, Cubedo, Redondo, Maurel, Carrasco, Lopez-Martin, Sala, Meana, Ramos, Martinez-Serra, Lopez-Guerrero, Sevilla, Balana, Vaz, De Juan, Alemany, Poveda Tags: Chemotherapy, Translational Oncology Sarcomas Source Type: research

Hydrocortisone as an Intervention for Dexamethasone-Induced Adverse Effects in Pediatric Patients With Acute Lymphoblastic Leukemia: Results of a Double-Blind, Randomized Controlled Trial [Pediatric Oncology]
Conclusion Our results suggest that adding a physiologic dose of hydrocortisone to dexamethasone treatment can reduce the occurrence of serious neuropsychological adverse effects and sleep-related difficulties in pediatric patients with ALL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Warris, van den Heuvel-Eibrink, Aarsen, Pluijm, Bierings, van den Bos, Zwaan, Thygesen, Tissing, Veening, Pieters, van den Akker Tags: Developmental Therapeutics & Pharmacology, Acute Lymphoblastic Leukemia, Supportive Care Pediatric Oncology Source Type: research

Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study [Gynecologic Cancer]
Conclusion On the basis of the PFS, overall response rate, and tolerability of these two antivascular therapies, further evaluation is warranted for this chemotherapy-free regimen. Fosbretabulin in combination with bevacizumab increases the risk of hypertension. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Monk, Sill, Walker, Darus, Sutton, Tewari, Martin, Schilder, Coleman, Balkissoon, Aghajanian Tags: Chemotherapy Gynecologic Cancer Source Type: research

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse [Gynecologic Cancer]
Conclusion Neither farletuzumab dose met the study’s primary PFS end point. Prespecified subgroup analyses demonstrated that patients with CA-125 levels not more than three times the ULN and patients with higher farletuzumab exposure showed superior PFS and OS compared with placebo. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Vergote, Armstrong, Scambia, Teneriello, Sehouli, Schweizer, Weil, Bamias, Fujiwara, Ochiai, Poole, Gorbunova, Wang, OShannessy, Herzog Tags: Chemotherapy Gynecologic Cancer Source Type: research

Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer [Palliative and Supportive Care]
Conclusion We observed racial disparities in early supportive medication use among patients with stage IV breast cancer. Although they did not clearly attenuate end-of-life care disparities, medication use disparities may be of concern if they point to disparities in adequacy of symptom management given the potential implications for quality of life. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Check, Samuel, Rosenstein, Dusetzina Tags: Quality of Care, End of Life, Pain Control, Supportive Care, Palliative Care Palliative and Supportive Care Source Type: research

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study [Gastrointestinal Cancer]
Conclusion In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan. No responses were seen with single-agent cetuximab. The responses observed with the combination of cetuximab and irinotecan may reflect true drug synergy or persistent irinotecan sensitivity. The ICECREAM (Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Among Patients with a G13D Mutation) study demonstrates the need to prospectively evaluate hypotheses that were previously supported by retro...
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Segelov, Thavaneswaran, Waring, Desai, Robledo, Gebski, Elez, Nott, Karapetis, Lunke, Chantrill, Pavlakis, Khasraw, Underhill, Ciardiello, Jefford, Wasan, Haydon, Price, van Hazel, Wilson, Simes, Shapiro Tags: Translational Oncology, Gastrointestinal Gastrointestinal Cancer Source Type: research

Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study [Thoracic Oncology]
Conclusion The mutational spectrum is associated with smoking, body mass index, and other environmental factors, as well as with ERβ expression. Little association was observed between HPV and NSCLC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Kawaguchi, Koh, Ando, Ito, Takeo, Adachi, Tagawa, Kakegawa, Yamashita, Kataoka, Ichinose, Takeuchi, Serizawa, Tamiya, Shimizu, Yoshimoto, Kubo, Isa, Saka, Matsumura Tags: Epidemiology Thoracic Oncology Source Type: research

Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study [Breast Cancer]
Conclusion In women with breast cancer and an age distribution representative of routine clinical practice, trastuzumab-based regimens, including those without anthracyclines, were associated with an increased risk of cardiotoxicity. Sequential therapy increased the risk of hospital-based CHF events. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Thavendiranathan, Abdel-Qadir, Fischer, Camacho, Amir, Austin, Lee Tags: Epidemiology, Chemotherapy Breast Cancer Source Type: research

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial [Breast Cancer]
Conclusion Two years of adjuvant tamoxifen resulted in a long-term survival benefit in premenopausal patients with estrogen receptor–positive primary breast cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Ekholm, Bendahl, Ferno, Nordenskjold, Stal, Ryden Tags: Hormonal Therapy Breast Cancer Source Type: research